Genetic engineering of non-human animals for the production of chimeric antibodies
The invention provides non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing transgenic cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits. Certain aspects of the invention also relate to diagnostic and treatment methods using the antibodies of the invention.
1. A method of producing an antibody, or antigen-binding fragment thereof, the antibody or fragment comprising a human immunoglobulin light chain variable region (VL) polypeptide, comprising:
(a) immunizing a mouse with an antigen, wherein the mouse's genome comprises a transgene comprising (1) a plurality of immunoglobulin light chain variable (V) exons encoding human immunoglobulin light chain V polypeptides; (2) non-coding sequences between the V exons; (3) a plurality of immunoglobulin light chain joining (J) coding sequences encoding human immunoglobulin light chain J polypeptides; and (4) non-coding sequences between the J coding sequences; wherein the non-coding sequences between the V exons and the non-coding sequences between the J coding sequences are derived from mouse immunoglobulin non-coding sequences, wherein the transgene is capable of undergoing gene rearrangement to produce a polynucleotide sequence encoding the antibody or fragment comprising the immunoglobulin VL polypeptide;
(b) recovering from the mouse a genomic DNA or cDNA comprising a nucleotide sequence encoding the human immunoglobulin VL polypeptide; and
(c) recombinantly producing the human immunoglobulin VL polypeptide.
2. The method according to claim 1 , wherein the non-coding sequences between the V exons and the non-coding sequences between the J coding sequences are derived from mouse immunoglobulin light chain non-coding sequences.
3. The method according to claim 1 , wherein the non-coding sequences between the V exons and the non-coding sequences between the J coding sequences are selected from the group consisting of intronic sequences and cis regulatory sequences.
4. The method according to claim 3 , wherein the cis regulatory sequences are selected from the group consisting of promoters, enhancers, recombination signal sequences, splice acceptor sequences, and splice donor sequences.
5. The method according to claim 1 , wherein the V exons encode human kappa light chain V (Vκ) polypeptides.
6. The method according to claim 1 , wherein the V exons encode human lambda light chain V (Vλ) polypeptides.
7. The method according to claim 1 , wherein the J coding sequences encode human kappa light chain J (Jκ) polypeptides.
8. The method according to claim 1 , wherein the J coding sequences encode human lambda light chain J (Jλ) polypeptides.
9. The method according to claim 1 , wherein (1) the non-coding sequences between the V exons and (2) the V exons are from non-orthologous immunoglobulin loci.
10. The method according to claim 1 , wherein the transgene further comprises a coding sequence encoding an immunoglobulin light chain constant (CL) polypeptide.
11. The method according to claim 10 , wherein the coding sequence encoding the immunoglobulin CL polypeptide encodes a lambda light chain constant (Cλ) polypeptide.
12. The method according to claim 10 , wherein the coding sequence encoding the immunoglobulin CL polypeptide encodes a kappa light chain constant (Cκ) polypeptide.
13. The method according to claim 10 , wherein the immunoglobulin CL polypeptide is a mouse immunoglobulin CL polypeptide.
14. The method according to claim 1 , wherein the transgene further comprises mouse non-coding sequences upstream of the V exons.
15. The method of claim 14 , wherein the non-coding sequences upstream of the V exons are selected from promoters and enhancers.
16. The method according to claim 1 , wherein the transgene further comprises mouse non-coding sequences downstream of the J coding sequences.
17. The method according to claim 16 , wherein the non-coding sequences downstream of the J coding sequences are selected from polyadenylation sites and 3′ untranslated regions.
18. The method according to claim 11 , wherein the transgene comprises (1) a plurality of human immunoglobulin light chain variable Vλ exons encoding human immunoglobulin light chain variable Vλ polypeptides; (2) mouse non-coding sequences between the Vλ exons; (3) 2-7 immunoglobulin light chain Jλ-Cλ coding sequence pairs, wherein each Jκ sequence encodes a human immunoglobulin light chain Jλ polypeptide and each Cλ sequence encodes a mouse immunoglobulin light chain Cλ polypeptide; (4) mouse non-coding sequences between the Jλ coding sequences and the Cλ coding sequences in the Jλ-Cλ coding sequence pairs; and (5) mouse non-coding sequences between the Jλ-Cλ coding sequence pairs.
19. The method according to claim 12 , wherein the transgene comprises (1) a plurality of human immunoglobulin light chain variable Vκ exons, encoding human immunoglobulin light chain variable Vκ polypeptides; (2) mouse non-coding sequences between the Vκ exons; (3) a plurality of human immunoglobulin light chain variable Jκ coding sequences encoding human immunoglobulin light chain variable Jκ polypeptides; (4) mouse non-coding sequences between the Jκ coding sequences; and (5) a Cκ coding sequence encoding a mouse immunoglobulin light chain constant Cκ polypeptide.
20. The method according to claim 1 , further comprising a step of appending the nucleotide sequence encoding the human immunoglobulin VL polypeptide of step (b) to a DNA encoding a human light chain constant (CL) region to generate a DNA encoding a fully human VL-CL polypeptide.
21. The method according to claim 1 , wherein the mouse's genome further comprises a second transgene encoding an immunoglobulin heavy chain, or a portion thereof.
22. The method according to claim 1 , further comprising a step of isolating B lymphocytes from said mouse, wherein one or more of said B lymphocytes produces an antigen-specific antibody that specifically binds to the target antigen.
23. The method according to claim 22 , further comprising a step of screening said B lymphocytes to identify the one or more B lymphocytes that produces the antigen-specific antibody that specifically binds to the target antigen.
24. The method according to claim 23 , wherein the recovering step (b) comprises isolating the genomic DNA or cDNA comprising the nucleotide sequence encoding the human immunoglobulin VL polypeptide from the one or more B lymphocytes that produces the antigen-specific antibody that specifically binds to the target antigen.
25. The method according to claim 22 , wherein the method further comprises generating hybridomas from the isolated B lymphocytes.
26. The method according to claim 25 , wherein the recovering step (b) comprises isolating the genomic DNA or cDNA comprising the nucleotide sequence encoding the human immunoglobulin VL polypeptide from the hybridoma that produces the antigen-specific antibody that specifically binds to the target antigen.
27. The method according to claim 22 , further comprising implementing the nucleotide sequence encoding the human immunoglobulin VL polypeptide into an in vitro antibody display system.
28. The method according to claim 24 , further comprising implementing the nucleotide sequence encoding the human immunoglobulin VL polypeptide into an in vitro antibody display system.
29. The method according to claim 26 , further comprising implementing the nucleotide sequence encoding the human immunoglobulin VL polypeptide into an in vitro antibody display system.